Listen
Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use in the extension of indication in the treatment in adults of visual impairment due to macular oedema secondary to a branch retinal vein occlusion (BRVO) or a central retinal vein occlusion (CRVO).
-
Clinical Benefit
| Substantial |
The actual benefit of LUCENTIS 10 mg/ml injectable solution is substantial. |
Clinical Added Value
| minor |
LUCENTIS provides a minor improvement in actual benefit (IAB IV) compared with OZURDEX in the treatment of visual impairment due to a macular oedema secondary to retinal venous branch occlusion or a central retinal venous occlusion. |
English version
Contact Us
Évaluation des médicaments
